Overview
McKesson Corporation is a healthcare distribution and services company. Its businesses distribute medicines and other healthcare products and provide related services, including specialty distribution and support for oncology and multispecialty practices. Its operations are centered on the United States and Canada, with businesses including North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.[1][2][3]
McKesson’s stated purpose is “Advancing health outcomes for all.” The company traces its origins to 1833. In fiscal 2026, it reported revenue of $403.430 billion and a workforce of more than 43,000.[4][5][6][7] [1][2][6][3][4][5][7]
Products & services
McKesson’s products and services span pharmaceutical, specialty-care, technology and medical-surgical markets. Its North American Pharmaceutical business distributes branded, generic, specialty, biosimilar and over-the-counter medicines and other healthcare products, and provides pharmacies with financial, operational and clinical solutions, consulting, outsourcing and technology services.[1] Oncology & Multispecialty offers specialty-drug distribution, group purchasing, infusion and direct-to-patient pharmacy services, vaccine distribution, and cell- and gene-therapy services through InspiroGene™. Its offerings also include practice technology and consulting; Ontada® provides oncology-practice software and supports real-world evidence research, clinical data insights, EHR-to-electronic-data-capture capabilities, advisory services and education. The business also includes PRISM Vision, Sarah Cannon Research Institute and the U.S. Oncology Network.[2][8]
Prescription Technology Solutions provides medication-access and affordability services, prescription decision support and price transparency, benefit insight, dispensing support, patient enrollment, third-party logistics and wholesale-distribution support. Its network connects with most EHR systems, more than 50,000 pharmacies and more than 1 million providers, among other healthcare partners.[9] Medical-Surgical Solutions supplies medical-surgical products, laboratory equipment, pharmaceutical distribution and logistics to non-acute care settings; its portfolio includes more than 270,000 national-brand products and 4,000-plus own-line products.[10] Health Mart® supports a network of about 3,900 independently owned pharmacies with operational, workforce, patient-health, marketing, merchandising and audit support.[11]
In fiscal 2026, North American Pharmaceutical generated $336.652 billion, or approximately 83.4% of McKesson’s $403.430 billion in consolidated revenue; Oncology & Multispecialty generated $48.423 billion (12.0%), Prescription Technology Solutions $5.805 billion (1.4%), and Medical-Surgical Solutions $11.507 billion (2.9%). These percentages are approximate calculations from reported segment revenues.[6] Services accounted for less than 1% of North American Pharmaceutical segment revenue, approximately 7% of Oncology & Multispecialty, approximately 43% of Prescription Technology Solutions and less than 1% of Medical-Surgical Solutions.[12] [1][2][8][9][10][11][6][12]
Geographic presence
McKesson’s latest annual reporting year is FY2026, ended March 31, 2026. Its core disclosed geographic markets are the United States and Canada: the North American Pharmaceutical segment serves customers in both countries, while the company describes its Medical-Surgical Solutions and Oncology & Multispecialty operations as U.S.-focused. McKesson reported foreign operations at approximately 4% of consolidated revenue in FY2026 and FY2025, but did not provide a country-level revenue breakdown or a separate U.S.-versus-Canada split. The FY2026 foreign-operations figure includes the period before the January 30, 2026 sale of its Norway businesses.[13][14][12]
At March 31, 2026, McKesson reported more than 43,000 employees worldwide: approximately 38,000 in the U.S., 5,000 in Canada, and 400 elsewhere. Its corporate headquarters is in Irving, Texas, and McKesson Canada’s head office is in Montréal; the company also describes distribution centers, pharmacies, and offices across the U.S. and Canada.[6][15] [13][14][12][6][15]
Business segments
For fiscal 2026, McKesson reported four operating segments. North American Pharmaceutical distributes branded, generic, specialty, biosimilar and over-the-counter medicines and other healthcare products in the U.S. and Canada, and provides related pharmacy solutions; revenue was $336.7 billion, approximately 83.4% of consolidated revenue.[1][6] Oncology & Multispecialty provides specialty-drug distribution and services to oncology and other specialty practices, including infusion, direct-to-patient pharmacy, technology and practice solutions; revenue was $48.4 billion (12.0%).[2][6]
Prescription Technology Solutions provides medication-access solutions connecting patients and organizations across the prescription journey; revenue was $5.8 billion (1.4%).[9][6] Medical-Surgical Solutions supplies medical-surgical products, laboratory equipment and related services, principally to U.S. non-acute care providers; revenue was $11.5 billion (2.9%).[10][6] The company also reported $1.0 billion in “Other” revenue (0.3%), including its former Norwegian operations; this is a revenue category, not one of the four reportable segments. Consolidated revenue was $403.4 billion.[12][6] [1][6][2][9][10][12][16][17]
Company history
Founded in 1833 by John McKesson and Charles Olcott as a drug-import and wholesale business, McKesson grew from its early roots into a nationwide pharmaceutical distributor. In the 1970s, it introduced The Economost, an electronic order-transmission system for pharmaceutical orders.[5][18][19]
In 1999, McKesson merged with healthcare-software company HBO & Company, becoming McKesson HBOC; John Hammergren became CEO that year. The company later expanded through acquisitions including US Oncology in 2010, PSS World Medical in 2013 and Celesio in 2014, extending its reach in oncology services, medical distribution and European operations.[20][21][22][23][24]
From 2016 to 2018, McKesson acquired Canadian pharmacy operator Rexall and medication-access businesses CoverMyMeds and RxCrossroads, and combined most of its technology-solutions business with Change Healthcare to form a healthcare information-technology company. McKesson completed the split-off of its Change Healthcare interest in 2020. Brian Tyler succeeded Hammergren as CEO in April 2019.[25][26][27][28][29][30][31]
In the 2020s, McKesson sold several European operations and completed the sale of its Canadian Rexall and Well.ca businesses in December 2024. It also acquired an 80% controlling interest in ophthalmology and retina-services provider PRISM Vision Holdings in April 2025.[32][33][34][35][36] [19][31][35][36][5][18][20][21][22][23][24][25][26][27][28][29][30][32][33][34]
Sources
- MCKESSON CORP — Full financial report (2026 Y)
- www.mckesson.com[3]
- www.mckesson.com[4]
- www.mckesson.com[5]
- www.mckesson.com[7]
- www.mckesson.com[15]
- www.sec.gov[16]
- investor.mckesson.com[17]
- www.mckesson.com[18]
- www.sec.gov[20]
- www.mckesson.com[21]
- www.sec.gov[22]
- investor.mckesson.com[23]
- investor.mckesson.com[24]
- investor.mckesson.com[25]
- investor.mckesson.com[26]
- investor.mckesson.com[27]
- investor.mckesson.com[28]
- investor.mckesson.com[29]
- investor.mckesson.com[30]
- investor.mckesson.com[32]
- investor.mckesson.com[33]
- investor.mckesson.com[34]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore MCKESSON CORP in Finbar ↗